1-[4-(2-二乙基氨基乙氧基)苯基]-1-苯基-2-(对茴香基)乙醇 | 67-98-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 1-[4-(2-二乙基氨基乙氧基)苯基]-1-苯基-2-(对茴香基)乙醇
• 英文名称: ethamoxytriphetol
• 英文别名: Ethamoxytriphenol；1-<4-(2-Diethylamino-ethoxy)-phenyl>-1-phenyl-2-(4-methoxy-phenyl)-ethanol；1-<4-(2-Diethylamino-ethoxy)-phenyl>-2-(4-methoxy-phenyl)-1-phenyl-ethanol；1-[p-(2-diethylaminoethoxy)-phenyl]-2-(p-methoxyphenyl)-1-phenylethanol；1-[4-[2-(diethylamino)ethoxy]phenyl]-2-(4-methoxyphenyl)-1-phenylethanol
• CAS: 67-98-1
• 化学式: C₂₇H₃₃NO₃
• 分子量: 419.564
• InChiKey: KDYQVUUCWUPJGE-UHFFFAOYSA-N

物化性质

• 沸点：
  537.01°C (rough estimate)
• 密度：
  1.1111 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Methods of treating hormone-related conditions using cyclothiocarbamate derivatives
  申请人：Wyeth

  公开号：US20040006060A1

  公开（公告）日：2004-01-08

  The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I or formula II, or tautomers thereof, in a regimen which involves delivering one or more of a selective estrogen receptor modulator, wherein formula I is: 1 and wherein R 1 -R 5 and Q 1 are defined as described herein. Methods of providing hormone replacement therapy and for treating carcinomas, dysfunctional bleeding, uterine leiomyomata, endometriosis, and polycystic ovary syndrome is provided which includes delivering a compound of formula I and a selective estrogen receptor modulator are also described.

  本发明提供了一种诱导避孕的方法，包括向女性投递包含公式I或公式II的化合物或其互变异构体的组合物，并且涉及的给药方案包括投递一种或多种选择性雌激素受体调节剂，其中公式I是：1，其中R1-R5和Q1如本文所述定义。本发明还提供了一种提供激素替代疗法以及治疗癌变、功能失调性出血、子宫肌瘤、子宫内膜异位症和多囊卵巢综合征的方法，包括投递公式I的化合物和一种选择性雌激素受体调节剂，这些方法也在此描述。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Novel lipidomimetic compounds and uses thereof
  申请人：Koninklijke Philips Electronics N.V.

  公开号：EP2535326A1

  公开（公告）日：2012-12-19

  Disclosed are lipidomimetic compounds of formula I wherein: G represents a group satisfying formula II:          HO-CH2-CH(OH)-CH2-O}p-CH2-C(=O)-O-CH2}q-     formula II each n independently is an integer from 1-30; p is an integer from 1-10; q is 0 or 1. These compounds can be added to the lipid bilayer of thermosensitive liposomes, for the purpose of aiding in the prevention of leakage of the liposomes' contents at 37°C, and retarding clearance from circulation.

  揭示了具有以下结构的脂类拟拟物化合物：其中：G代表满足以下结构的基团II：         HO-CH2-CH(OH)- -O}p- -C(=O)-O- }q-        结构II每个n独立地是1-30之间的整数；p是1-10之间的整数；q为0或1。这些化合物可以添加到热敏感脂质体的脂质双层中，以帮助防止在37°C时脂质体内容物的泄漏，并延缓从循环中清除。
• Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers
  申请人：UNIVERSITY OF ILLINOIS CHICAGO

  公开号：US20140018435A1

  公开（公告）日：2014-01-16

  The invention provides for compositions for transdermal delivery of a therapeutic agent associated with a surface modified poly(amidoamine) PAMAM dendrimer, wherein the surface modified dendrimer increased skin penetration of the therapeutic agent. The invention particularly provides for compositions and methods for transdermal delivery of anticancer and chemo-preventive agents.

  本发明提供了一种与表面修饰的聚酰胺胺（PAMAM）树状分子相关的治疗剂经皮递送的组合物，其中表面修饰的树状分子增加了治疗剂的皮肤渗透性。本发明特别提供了用于经皮递送抗癌和化学预防剂的组合物和方法。